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All-trans retinoic acid protects against the development of
HIV-associated nephropathy (HIVAN) in HIV-1 transgenic mice
(Tg26). In vitro, all-trans retinoic acid inhibits HIV-induced
podocyte proliferation and restores podocyte differentiation
markers by activating its receptor-a (RARa). Here, we report
that Am580, a water-soluble RARa-specific agonist, attenuated
proteinuria, glomerosclerosis, and podocyte proliferation, and
restored podocyte differentiation markers in kidneys of Tg26
mice. Furthermore, RARa/ Tg26 mice developed more
severe kidney and podocyte injury than did RARaþ / Tg26
mice. Am580 failed to ameliorate kidney injury in RARa/
Tg26 mice, confirming our hypothesis that Am580 acts
through RARa. Although the expression of RARa-target genes
was suppressed in the kidneys of Tg26 mice and of patients
with HIVAN, the expression of RARa in the kidney was not
different between patients with HIVAN and minimal change
disease. However, the tissue levels of retinoic acid were
reduced in the kidney cortex and isolated glomeruli of Tg26
mice. Consistent with this, the expression of two key enzymes
in the retinoic acid synthetic pathway, retinol dehydrogenase
type 1 and 9, and the overall enzymatic activity for retinoic
acid synthesis were significantly reduced in the glomeruli of
Tg26 mice. Thus, a defect in the endogenous synthesis of
retinoic acid contributes to loss of the protection by retinoic
acid in HIVAN. Hence, RARa agonists may be potential agents
for the treatment of HIVAN.
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Retinoic acids (RAs) are metabolites of vitamin A that have
multiple cellular functions including inhibition of prolifera-
tion, induction of cell differentiation, regulation of apoptosis,
and inhibition of inflammation.1 Vitamin A (retinol) is
converted into retinal by retinol dehydrogenases (RDHs),
and retinal is converted into RA by retinal dehydrogenases.2
RA concentration is also regulated by catabolism via Cyp26.3
The kidney is a major organ of RA synthesis.4,5 During
kidney development, RA affects tubulogenesis and nephron
number.6 In addition to its established benefits for the
treatment of acute promyelocytic leukemia, RA has been
found to provide protection in multiple experimental models
of kidney disease including mesangioproliferative glomeru-
lonephritis, puromycin-induced nephrosis, lupus nephritis,
and diabetic nephropathy.5,7–11
Human immunodeficiency virus (HIV)-associated kidney
disease (HIVAN) remains a leading cause of end-stage renal
disease among young African Americans.12 The unique
feature of collapsing focal segmental glomerulosclerosis in
HIVAN is characterized by podocyte proliferation and
dedifferentiation.13–15 HIV-infected podocytes express increa-
sed levels of cyclin A, E, and D, and reduced levels of p27 and
p57.15,16 Podocytes also lose differentiation markers includ-
ing synaptopodin, nephrin, and Wilms tumor 1 (WT-1).13,14
Local HIV-1 infection is responsible for podocyte injury.17
Transgenic mice expressing HIV-1 genes in podocytes develop
a kidney disease identical to HIVAN.18,19 HIV infection of
cultured podocytes causes proliferation and dedifferentiation
via Nef-induced Src–Stat3 (signal transducer and activator
of transcription 3) and MAPK (mitogen-activated protein
kinase) 1 and 2 pathways.20 Although a combination anti-
retroviral regimen improves patient survival and ameliorates
kidney disease,21 additional treatments for HIVAN are still
lacking, particularly for patients who do not respond to
antiretroviral treatment.
Recently, we found that all-trans retinoic acid (ATRA)
reduces proteinuria and glomerulosclerosis in the HIV-1
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 7 April 2010; revised 30 August 2010; accepted 5 October
2010; published online 8 December 2010
Correspondence: John C. He, Department of Medicine/Nephrology, One
Gustave L Levy Place, Box 1243, Mount Sinai School of Medicine, New York,
New York 10029, USA. E-mail: cijiang.he@mssm.edu
9These authors contributed equally to this work.
624 Kidney International (2011) 79, 624–634
transgenic mouse, Tg26, which is the most robust animal
model of human HIVAN.22 We also found that ATRA inhibits
HIV-induced cell proliferation and restores differentiation
markers in HIV-infected podocytes through activation of
cyclic adenosine monophosphate production.22 ATRA also
inhibits MAPK phosphorylation through activation of MKP1
(MAPK phosphatase 1) in podocytes.23 In addition, we find
that Am580, a specific retinoic acid receptor-a (RARa)
agonist, stimulates cyclic adenosine monophosphate produc-
tion, inhibits HIV-induced podocyte proliferation, and
promotes podocyte differentiation in vitro, similar to what
we had observed with ATRA.22 Furthermore, the effects of
ATRA on podocytes are reduced by a specific RARa
antagonist (Ro-41-5253). These data suggest that RARa is
required for the antiproliferative and differentiation effects of
ATRA on HIV-infected podocytes.
As both the animal and in vitro studies strongly suggest a
beneficial role of ATRA in kidney disease, a phase II clinical
study has been approved for the use of ATRA to treat
patients with steroid-resistant minimal change disease, focal
segmental glomerulosclerosis, and HIVAN (ClinicalTrials.gov
Identifier NCT00098020). ATRA has a significant side-effect
profile in patients.24 Previous studies suggest that the side
effects of RA are mediated mostly through RARg. Am580, a
specific RARa agonist, causes less side effects than ATRA.25,26
In this study, we found that Am580 protects Tg26 against
renal injury, similar to ATRA. Using RARa knockout mice we
determined that the Am580 acts through a RARa-dependent
pathway to confer protection against podocyte injury and
kidney disease. Tissue levels of RA and the expressions of
key enzymes in the RA synthetic pathway (RDH1 and RDH9)
are reduced in the kidneys of Tg26, suggesting that
HIV-associated reduction in RA synthesis contributes to the
development of HIVAN.
RESULTS
Am580 reduced proteinuria and glomerulosclerosis in Tg26
As our previous study suggests that RARa has a key role in
mediating the protective effects of RA on podocytes,22 we
wanted to determine whether Am580, a specific agonist for
RARa, improves kidney disease similar to what we had
observed with ATRA. Both Tg26 and their littermates
(n¼ 20) were treated daily with Am580-containing chow
(0.3mg/kg/day) or control chow (prepared similarly without
Am580) from the age of 4 weeks, and were killed at the age of
12 weeks. We found that Am580 prevented kidney hyper-
trophy and preserved renal function in Tg26 compared with
mice treated with the control chow (Table 1). Also, Am580
significantly diminished proteinuria and improved glomer-
ulosclerosis, podocyte hypertrophy, and tubular injury in
Tg26 compared with the mice treated with the control chow
(Table 2 and Figure 1). Our previous in vitro studies suggest
that ATRA inhibits cell proliferation and restores differentia-
tion in HIV-infected podocytes through activation of
RARa.22 Therefore, we used orally administered Am580 to
determine if a RARa agonist would have a similar effect on
the renal phenotype in vivo. By immunostaining, we found
that Am580 restored the expression of synaptopodin, a
podocyte differentiation marker, in the kidneys of Tg26
(Figure 2a). By co-immunostaining for both Ki67 and nestin,
we found that Am580 also inhibited HIV-induced podocyte
proliferation (Figure 2b). Nestin was used for podocyte
colocalization because studies by others and our group have
shown that the expression of nestin is preserved in diseased
kidneys.27,28 To further confirm these findings, we examined
the mRNA levels for synaptopodin, nephrin, WT-1, Ki67, and
cyclin E in glomeruli isolated from these mice by real-time
PCR. We found that expression of podocyte differentiation
markers were preserved in glomeruli isolated from Tg26 that
received Am580 (Figure 3a). Also, proliferation markers
including Ki67 and cyclin E were suppressed in glomeruli
isolated from Tg26 that received Am580 (Figure 3b). Changes
in markers of podocyte differentiation and proliferation were
also confirmed by western blot analysis (Figure 3c). These
findings suggest that Am580 prevents podocyte injury in vivo
similar to what we observed previously in vitro using ATRA.22
Table 1 | Am580 prevents kidney hypertrophy and improves renal function in Tg26
BW (g) KW (mg) KW/BW (mg/g) BUN Urine Pro/Cr ratio
WT+control diet 25.3±4.0 222±51 8.7±1.3 0.21±2.32 0.15±0.12
WT+Am580 24.8±3.7 220±43 8.8±1.4 0.22±1.89 0.18±0.61
Tg26+control diet 25.4±4.2 235±46 9.3±1.0 0.76±1.67 32.4±6.5
Tg26+Am580 25.1±3.4 225±63* 8.8±1.6* 0.25±0.22* 3.5±1.5*
Abbreviations: BUN, blood urea nitrogen; BW, body weight; Cr, creatinine; KW, kidney weight; Pro, protein; WT, wild type.
Tg26 and WT littermates were treated with either control diet or Am580 for a total of 8 weeks as described in the Materials and Methods. When mice were killed at the age of
12 weeks, BW and KW were recorded and their ratio (KW/BW) was calculated. BUN and urinary protein and creatinine levels were measured. Urine Pro/Cr ratio was calculated,
n=20.
*Po0.01 compared with Tg26+control diet group.
Table 2 | Am580 improves kidney injury in Tg26
GS
index
Podocyte
hypertrophy
Tubular
casts/cysts
WT+control diet 0 0 0
WT+Am580 0 0 0
Tg26+control diet 19.5±3.2 1.9±0.9 10.2±2.5
Tg26+Am580 2.7±1.1* 0* 1.5±1.2*
Kidney histological analysis was performed in wild type (WT) and Tg26 treated with
either control diet or Am580. Glomerulosclerosis (GS) index, podocyte hypertrophy,
and tubular casts/cysts were quantified as described in the Materials and Methods,
n=20.
*Po0.001 compared with Tg26+control diet.
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WT + CL diet Tg26 + CL dietWT + Am580 Tg26 + Am580
Figure 1 |Kidney histology. Wild-type (WT) and Tg26 mice were treated with either vehicle or Am580 as described in the Materials
and Methods. The representative pictures of kidney histology (hematoxylin and eosin (H&E) staining) of these mice are shown. Top and
bottom panels are representative fields showing glomerular and tubulointerstitial area, respectively (original magnification  200).
WT + CL diet Tg26 + CL dietWT + Am580 Tg26 + Am580
Synap
Ki67
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b
Figure 2 | Immunostaining. Kidney sections from mice treated with either vehicle or Am580 were used for immunohistochemistry
of (a) synaptopodin (Synap), a podocyte differentiation marker, and for (b) immunofluorescence of Nestin and Ki67. Nestin is a podocyte-
specific marker. Ki67 is a marker for proliferating cells. The representative pictures are shown (n¼ 5).
626 Kidney International (2011) 79, 624–634
or ig ina l a r t i c l e KK Ratnam et al.: Retinoids and kidney disease
Knockout of RARa in Tg26 aggravated proteinuria,
glomerulosclerosis, and podocyte injury
To further assess the critical role of RARa in HIVAN, we
hypothesized that knockout of RARa in the Tg26 back-
ground would aggravate kidney injury. RARa/ mice were
crossed with Tg26 as described in the Materials and Methods
to generate RARaþ /þ Tg26, RARaþ / Tg26, RARa/
Tg26, and their littermates (wild type (WT)) as controls.
Mice from the same litter were used for comparison.
We found that RARa/ mice developed more severe
proteinuria and kidney damage compared with RARaþ /
Tg26 and RARaþ /þ Tg26 (Table 3 and Figure 4). By real-
time PCR, we found that the expression of podocyte
differentiation markers was further suppressed in glomeruli
isolated from RARa/ Tg26 mice compared with RARaþ /þ
Tg26 and RARaþ / Tg26 (Figure 5a). The expression of
proliferation markers (Ki67 and cyclin E) was further
increased in glomeruli isolated from RARa/ Tg26
compared with RARaþ / and RARa/ mice (Figure 5b).
These changes could also be the result of differences in the
expression of the HIV transgene. To eliminate this possibility,
we measured the expression of nef, one of the important
regulatory genes in the pNL4-3 deletion mutant used to
generate the transgenic mice. We found that the expression of
HIV-1 nef was not different among RARa/ Tg26,
RARaþ /þ Tg26, and RARaþ / Tg26 mice (Figure 5c).
In addition, the changes in the expression of markers of
podocyte proliferation and differentiation were confirmed at
protein levels by western blot (Figure 5d). Taken together,
these data suggest that knockout of RARa caused more severe
podocyte injury and kidney damage in Tg26, and RARa likely
acts as an endogenous protective pathway to prevent the
development and the progression of kidney disease.
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Figure 3 |Real-time PCR. Glomeruli were isolated from mice treated with either control vehicle (CL) or Am580 as described. Total RNA was
isolated from these glomeruli for real-time PCR analysis of genes associated with (a) podocyte differentiation (synaptopodin, nephrin,
and WT-1) and (b) podocyte proliferation (Ki67 and cyclin E). The ratio of tested genes to tubulin expression was calculated. The ratio of
treated mice to control wild type (WT) is shown, n¼ 10, *Po0.01. (c) Protein lysates from these glomeruli were used for western blot
analysis for the above podocyte differentiation and proliferation markers. The representative blots of at least three independent
experiments are shown.
Table 3 | Knockout of RARa aggravates kidney injury in Tg26
Urine
Pro/Cr ratio
GS
index
Podocyte
hypertrophy
Tubular
casts/cysts
RARa+/+ 0.12±0.10 0 0 0
RARa+/+ Tg26 33.4±15.6 18.5±11.1 1.2±0.8 9.4±5.6
RARa+/ 0.21±0.22 0 0 0
RARa+/ Tg26 35.1±19.5 21.7±7.8 1.3±0.5 8.4±3.9
RARa/ 0.29±0.32 0 0 0
RARa/ Tg26 140±89* 45.5±22.9* 2.3±0.8* 23.9±14.5*
Abbreviations: Cr, creatinine; GS, glomerulosclerosis; Pro, protein; RAR, retinoic acid
receptor.
A comparison of proteinuria (urine Pro/Cr ratio), GS index, podocyte hypertrophy,
and tubular casts/cysts was performed between RARa+/+, RARa+/+ Tg26, RARa+/,
RARa+/ Tg26, RARa/, and RARa/ Tg26 mice, n=20.
*Po0.001 compared with the Tg26 group.
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x200
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Figure 4 |Kidney histology. RARaþ /þ , RARa/, RARaþ /þ Tg26, and RARa/ Tg26 mice were killed at the age of 12 weeks for
histology analysis. The representative fields of hematoxylin and eosin (H&E) staining are shown. Original magnification (top panel)  200;
(low panel)  400.
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Figure 5 |Real-time PCR. Glomeruli were isolated from RARaþ /þ , RARa/, RARaþ /þ Tg26, and RARa/ Tg26 mice at 12 weeks of
age. Total RNA was isolated from glomeruli for real-time PCR analysis of genes indicative of (a) podocyte differentiation (synaptopodin,
nephrin, and WT-1) and (b) proliferation (Ki67 and cyclin E). The ratio of tested genes to tubulin gene was calculated. The ratio of treated
mice to wild type (WT) was shown, n¼ 10, *Po0.01. (c) Real-time PCR was also performed to verify the expression of HIV-1 nef gene in the
glomeruli of these mice. (d) Glomerular lysates were used for western blot analysis of the above podocyte differentiation and proliferation
markers. The representative blots of at least three independent experiments are shown.
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Am580 failed to improve proteinuria and glomerulosclerosis
in Tg26
Next, to establish whether the beneficial effect of Am580 is
mediated through agonism of RARa, we evaluated the
impact of Am580 on the development of kidney disease in
Tg26 mice lacking RARa. RARa/ Tg26, RARaþ / Tg26,
and RARaþ /þ Tg26 mice were fed with Am580 or control
diet from 4 weeks of age and killed at 12 weeks of age as
described in the Materials and Methods. We found that
whereas Am580 significantly reduced proteinuria and kidney
damage in RARaþ /þ Tg26 and RARaþ / Tg26, it failed
to improve proteinuria, glomerulosclerosis, and tubular
injury in RARa/ Tg26 (Table 4). These data further
confirm a critical role of RARa in mediating the protective
effects of Am580 in Tg26.
Expression of RARa and RARb in kidneys of Tg26 mice and
patients with HIVAN
As our studies suggest a critical role of RARa in mediating
the protective effects of retinoids in the HIVAN model, we
speculated that the basal expression of RARa between Tg26
and WT kidneys could be different. However, the expression
of RARa was not different between Tg26 and WT kidneys by
immunostaining (Figure 6a). Kidneys from RARa/ mice
were used as the negative control. In contrast, the expression
of RARb, which is a target gene of RARa, was signifi-
cantly downregulated in kidneys of Tg26 and in kidneys of
RARa/ mice (Figure 6a). Similarly, the expression of
RARa was not different between kidneys from patients
with HIVAN and patients with minimal change disease, and
the expression of RARb was significantly downregulated in
Table 4 | Am580 failed to improve kidney disease in RARa/
Tg26
Urine
Pro/Cr ratio
GS
index
Podocyte
hypertrophy
Tubular
casts/cysts
RARa+/+ Tg26 control diet 31.2±7.3 16.5±3.1 1.2±0.8 9.4±5.6
RARa+/+ Tg26 Am580 2.6±1.6* 1.7±1.4* 0* 2.5±1.4*
RARa+/ Tg26 control diet 33.1±10.5 12.7±7.4 1.3±0.5 6.9±1.3
RARa +/ Tg26 Am 580 3.4.1±1.5* 1.9±1.2* 0* 1.9±0.9*
RARa/ Tg26 control diet 123.2±22.3 41.2±12.3 3.5±1.2 21.6±7.2
RARa/ Tg26 Am580 110±11.2 38.3±9.2 3.3±0.9 19.7±6.4
Abbreviations: Cr, creatinine; GS, glomerulosclerosis; Pro, protein; RAR, retinoic acid
receptor.
RARa+/+ Tg26, RARa+/ Tg26, and RARa/ Tg26 mice were treated with either
control diet or Am580 from 4 to 12 weeks of age. Then, mice were killed for analysis
of proteinuria and histology as summarized here, n=20.
*Po0.001 compared with RARa+/+ Tg26 control diet.
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Figure 6 | Immunostaining for retinoic acid receptor (RAR)a and RARb. (a) Immunostaining was performed in kidneys of wild-type (WT),
Tg26, and RARa/ mice using anti-RARa and anti-RARb antibodies (Santa Cruz Biotechnology). (b) Immunostaining was also performed in
kidneys from patients with human immunodeficiency virus (HIV)-associated kidney disease (HIVAN) and with minimal change disease (MCD) using
anti-human RARa and RARb antibodies (Santa Cruz Biotechnology). The representative pictures are shown here (n¼ 5). (c) Total RNA was isolated
from glomeruli of Tg26 and WT littermates. Real-time PCR was performed for RARa, RARb, RORA (retinoid-related orphan receptor-a), and
RARRES1 (retinoic acid receptor responder protein 1). Fold change of gene expression in Tg26 relative to WT is shown here. *Po0.01, n¼ 10.
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kidneys from patients with HIVAN (Figure 6b). These
findings were confirmed by real-time PCR showing that
mRNA levels of RARa were not different between Tg26 and
WT kidneys, whereas RARb expression was suppressed in
Tg26 kidneys (Figure 6c). Furthermore, we found that
RARRES1 (retinoic acid receptor responder protein 1) and
RORA (retinoid-related orphan receptor-a) were also
significantly reduced in glomeruli of Tg26 (Figure 6c).
Retinoid synthesis in Tg26 kidneys
We were surprised to find that RARa expression was not
different in Tg26 kidneys, and hence we hypothesized that
endogenous RA synthesis might be impaired instead. We
measured kidney tissue levels of retinol and RA and found
that whereas retinol was not different in kidney cortices
between WT and Tg26 mice, RA levels were signifi-
cantly reduced in Tg26 kidneys compared with WT kidneys
(Figure 7a). As we are interested in RA synthesis in podo-
cytes, we also measured retinol and RA levels in isolated
glomeruli. Similar to the level of RA in kidney cortices, RA
expression is suppressed in isolated glomeruli of Tg26
compared with WT mice, whereas retinol levels did not
differ between these animals (Figure 7b). The suppression of
RA in isolated glomeruli was more pronounced than in
kidney cortices. Interestingly, the amount of RA per gram of
tissue was much higher in isolated glomeruli than in kidney
cortices. To determine whether the reduction of RA synthesis
in Tg26 was tissue specific, we also compared the levels of
retinol and RA in the liver of Tg26 and WT mice. We found
that both retinol and RA levels were similar in the liver of WT
and Tg26 mice (Figure 7c). This suggests that the impairment
of RA synthesis in kidneys of Tg26 is tissue specific. In
addition, we determined the rate of RA synthesis in isolated
glomeruli by measuring the conversion rate of retinol to RA
in the presence of glomerular lysates from either Tg26 or WT
mice. We confirmed that glomerular lysates of Tg26, when
compared with lysates of WT, had a reduced rate of retinol to
RA conversion, which suggests that synthesis of RA is lower
in Tg26 (Figure 7d). To further investigate which enzyme(s)
involved in the synthesis of RA is responsible for the lower
RA level in Tg26 glomeruli, we analyzed the expression of
genes responsible for RA metabolism. We performed gene
expression microarray analysis on glomeruli isolated
from Tg26 and WT kidneys and generated an expression
profile of genes related to retinoid metabolism. We found
that two key enzymes of RA synthesis, RDH1 and RDH9,
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Figure 7 | Tissue levels of retinoids. Retinol (ROL) and retinoic acid (RA) levels were measured in (a) kidneys cortices, (b) isolated glomeruli,
and (c) livers of Tg26 and wild-type (WT) mice as described in the Materials and Methods (n¼ 5, *Po0.01). (d) The enzymatic activity of RA
synthesis was also determined in isolated glomeruli by measuring the conversion of retinol to RA, n¼ 5, *Po0.001. (e) Total RNA was
isolated from glomeruli of Tg26 and WT littermates. Real-time PCR were performed for retinol dehydrogenase (RDH)1, RDH9, and Cyp26A1.
Fold change of gene expression in Tg26 relative to WT is shown here, *Po0.01, n¼ 10. (f) Immunostaining of RDH1 was performed in
kidneys from patients with human immunodeficiency virus (HIV)-associated kidney disease (HIVAN) and minimal change disease (MCD).
The representative pictures of five individual patients are shown here.
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were significantly downregulated in the kidneys of Tg26,
whereas there was a significant increase in the expression of
Cyp26A1, which is an enzyme responsible for the degrada-
tion of RA. These findings were further confirmed by real-
time PCR (Figure 7e). Using immunostaining, we confirmed
that RDH1 expression is also suppressed in the kidney of
patients with HIVAN (Figure 7f). The expression of cellular
retinol binding protein was not different between Tg26 and
WT mice (Figure 7e). The expression of other enzymes in
the RA synthesis pathway, including retinal dehydrogenase
1, 2, and 4, was not suppressed in Tg26 glomeruli (data not
shown). Using real-time PCR, we confirmed that there was
no difference in the mRNA level of RDH1, RDH9, and
Cyp26A1 in the liver of Tg26 and WTmice (data not shown).
Taken together, these data indicate that endogenous synthesis
of RA is likely impaired in diseased kidneys, leading to the
loss of endogenous protective effects of RAs.
DISCUSSION
Although the incidence of HIVAN decreased in the highly
active antiretroviral therapy era, its prevalence is increasing
because of the aging of patients.21,29 Furthermore, highly
active antiretroviral therapy is only partially protective and
many patients with HIVAN ultimately progress to end-stage
renal disease.30 HIVAN remains the leading cause of end-
stage renal disease among young African Americans12 on
highly active antiretroviral therapy. Therefore, it is of
paramount importance to identify additional treatment
options for patients with HIVAN.
A large amount of evidence suggests that RA ameliorates
kidney injury in many animal models of kidney disease
including HIVAN. Unfortunately, treatment strategies using
RA are limited because of significant side effects from ATRA.
Our current study suggests that Am580, a RARa agonist,
improves kidney disease in an animal model of HIVAN
(Tg26) similar to ATRA. Am580 can be given orally. It has
significantly less side effects than ATRA because it targets
only RARa. In addition, it is believed that the side effects of
ATRA are mediated mostly by RARg.26 Our data suggest that
Am580 could be a potentially important drug in the
treatment of patients with HIVAN without causing signifi-
cant side effects. Recent studies suggest that Am580 inhibits
tumor oncogenesis in animal models with mammary tumor
through inhibition of proliferation and induction of
differentiation of tumor cells.31 No significant side effects
were reported in these animals treated with Am580.
Our studies using RARa-null mice further confirm the
critical role of RARa in kidney disease. Knockout of RARa
causes the loss of an endogenous protective pathway and
leads to a more aggressive kidney disease. The role of RARa
in kidney disease was further supported by the lack of
protection by Am580 in RARa/ Tg26 mice. These studies
strongly suggest that RARa is a potential therapeutic target to
treat patients with HIVAN. Further drug screening of RARa
agonists should be encouraged as an alternative or adjunctive
form of therapy for patients with HIVAN.
How RA improves kidney disease remains unclear. It has
been shown that RA has both anti-inflammatory and
antifibrosis effects.5,32 Recent studies suggest that RA can
also induce podocyte differentiation and maintain nephrin
expression in cultured podocytes.33 We found that ATRA
inhibits HIV-induced podocyte proliferation and restores
differentiation markers in HIV-infected podocytes via
activation of RARa.22 Our current findings show that
activation of RARa in vivo by a specific agonist protects
podocytes from injury, whereas knockdown of RARa
aggravates podocyte injury and disease severity. Taken
together, this indicates that RARa is a key molecule
mediating the protective effects of RA in podocytes.
Interestingly, we found that RARa-mediated target genes,
including RARb and RARRES1, were inhibited in kidneys of
Tg26. This suggests that the RARa-mediated protection is
impaired in Tg26 kidneys. However, the expression of RARa in
kidneys did not differ between Tg26 and the WT littermates.
The kidney is known to be a major organ for RA acid synthesis.
In this study, we measured the level of retinol and RA in the
renal cortex, isolated glomeruli, and liver of Tg26 and WTmice.
Interestingly, we found that the level of RA was significantly
suppressed in the Tg26 kidney cortex and even more suppressed
in the isolated glomeruli, whereas the level of retinol remained
unchanged. These findings suggest that RA synthesis is severely
impaired in the glomeruli of Tg26. The level of retinol and RA
in the liver was not different between Tg26 and WT. This
suggests that the suppression of RA in Tg26 is likely not a
generalized phenomenon. The measurement of key synthetic
enzymes involved in RA metabolism in the kidney revealed that
both RDH1 and RDH9 are severely suppressed in the kidneys of
Tg26, whereas Cy26a, a RA acid catalytic enzyme, is increased in
Tg26. Although we showed that the general enzymatic activity
of RA synthesis is markedly reduced in Tg26 glomeruli, we were
unable to measure the enzymatic activity of RDH1 and RDH9
because of the lack of isoform-specific antibodies. Our findings
suggest that the restoration of normal RA synthesis in kidneys
could be a potential therapeutic approach. The reasons for the
differential regulation of RDH1, RDH9, and Cy26a in Tg26 and
WT kidneys remain to be determined. Finally, Am580 might
be particularly effective in treating Tg26 mice or individuals
with HIVAN because Am580 is resistant to degradation by
Cyp26a,34,35 which we have found to be upregulated in HIVAN.
In conclusion, our findings demonstrate that endogenous
RA synthesis is impaired in diseased kidneys. RARa-mediated
signaling acts as an endogenous protective pathway to slow
the progression of kidney disease, and selective activation of
the RARa receptor may be a promising treatment option for
patients with HIV-related renal diseases.
MATERIALS AND METHODS
Generation of RARa–/– and RARa+/– Tg26 mice
RARa/ mice were provided by Dr Pierre Chambon, (Strasbourg,
France) as described.36 Derivation of a HIV-1 transgenic mouse line
(Tg26) that bears a defective HIV-1 provirus lacking gag-pol (Tg26)
has been described.37 Both RARa/ and Tg26 mice are in the
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same FVB/N background. RARa/ female mice were crossed with
male Tg26þ / (heterozygote) mice to generate RARaþ / Tg26þ /
mice. Then, we crossed male RARþ / Tg26þ / mice with female
RARþ / Tg26þ /mice to generate RARþ /þ Tg26þ /, RARþ /
Tg26þ /, RAR/ Tg26þ / mice, and their corresponding
littermates without the Tg26 gene. Mice generated from the same
litter of Tg26 mice were used in the studies. Genotyping by tail prep
and PCR were performed at 2 weeks of age as described.28
Treatment of animals with Am580
Tg26, RARþ / Tg26, RAR/ Tg26, and their corresponding
littermates (n¼ 20 per group including 10 male and 10 female mice
in each group) were fed Am580 at a concentration of 0.3mg/kg/day,
and the control foods, which were prepared similarly without
Am580. Am580 was a gift from Dr K Shudo (Research Foundation
ITSUU Laboratory, Molecular and Functional Bioscience, Japan).
The mice were fed these diets everyday from the age of 4 weeks to
12 weeks. Based on the daily measurement of food intake, the
average food intake ranged from 3.5 to 4.5 g/day per mouse.
Unrestricted water was provided throughout the duration of the
experiment. The mice were killed at 12 weeks of age for blood, urine,
and tissue collection by exposure to carbon monoxide. Body and
kidney weight were recorded. All animal studies were performed
according to the protocols approved by the institutional animal care
and use committee at the Mount Sinai School of Medicine.
Measurement of blood urea nitrogen, urine protein, and
creatinine
Mouse serum was collected for measurement of blood urea nitrogen
in the laboratory of Mount Sinai Hospital, New York using a urease-
based assay (Vitros BUN/UREA slides detected using Vitros 5,1 FS
Instrument, Ortho-Clinical Diagnostics, Rochester, NY). Urine
albumin was quantified by enzyme-linked immunosorbent assay
using a kit from Bethyl Laboratory (Houston, TX). Urine creatinine
levels were measured in the same samples using QuantiChrom
Creatinine Assay Kit (DICT-500; BioAssay Systems, Hayward, CA)
according to the manufacturer’s instruction. The urine albumin
excretion rate was expressed as the ratio of albumin to creatinine.
Quantitative histopathology
Mice were perfused with phosphate-buffered saline containing 4%
paraformaldehyde, and kidneys were further fixed in 4% paraformal-
dehyde for 2 h. Kidney tissue was embedded in paraffin by American
Histolabs (Gaithersberg, MD) and 3mm thick sections were stained
with periodic acid-Schiff. Renal histological abnormalities were scored
by a renal pathologist (VD’A) as previously described.31 The three
parameters scored included the percentage of glomeruli exhibiting
collapse and segmental or global sclerosis, the percentage of total renal
parenchyma occupied by tubular casts and/or microcysts, and the
severity of podocyte hypertrophy and hyperplasia (graded on a
semiquantitative scale (0–3þ ).38 For the latter parameter, podocyte
hypertrophy and hyperplasiawas graded as 0 (absent), 1þ (involving
1–25% of all glomeruli sampled), 2þ (involving 26–50% of
glomeruli), and 3þ (involving 450% of glomeruli) as described.39
An average of 50 glomeruli was sampled per animal.
Isolation of glomeruli from mice for western blot
and real-time PCR
Mouse glomeruli were isolated as described.40 Briefly, animals were
perfused with Hank’s buffered salt solution containing 2.5mg/ml
iron oxide and 1% bovine serum albumin. At the end of perfusion,
kidneys were removed, decapsulated, minced into 1-mm3 pieces,
and digested in Hank’s buffered salt solution containing 1mg/ml
collagenase A and 100U/ml deoxyribonuclease I. Digested tissue was
then passed through 100mm cell strainer and collected by
centrifugation. The pellet was resuspended in 2ml of Hank’s
buffered salt solution and glomeruli were collected using a magnet.
The purity of glomeruli was verified under microscopy and by
western blot analysis for podocyte-specific markers including
synaptopodin and WT-1.
Immunohistochemistry
Kidney sections from these mice and from kidney biopsies were
prepared as described.20 Human kidney biopsies from patients with
HIVAN and non-HIV patients with minimal change disease
were collected at Columbia University under a protocol approved
by its institutional review board. These biopsy samples were from
five patients with HIVAN and five patients with minimal change
disease, which was confirmed by a renal pathologist. Immunostain-
ing was performed using anti-synaptopodin (gifts of Dr Peter
Mundel), anti-RARa, anti-RARb, and anti-RDH1 (all retinoid-
related antibodies were purchased from Santa Cruz Biotechnology,
Santa Cruz, CA), and then followed by biotinylated secondary
antibodies (Vector Laboratories, Burlingame, CA) as described.
After staining, slides were mounted in Aqua Poly/Mount (Poly-
sciences, Warrington, PA) and photographed under an Olympus
BX60 microscope (Olympus Optical, Center Valley, PA) with a
digital camera. For colocalization studies, sections were incubated
with anti-Ki67 antibodies (Dako, Carpinteria, CA) together with
anti-nestin antibody (Santa Cruz Biotechnology) at room tempera-
ture for 1 h. After washing, sections were incubated with a
fluorophore-linked secondary antibody (Alexa Fluor 488 anti-rabbit
IgG and Alexa Fluor 568 anti-mouse IgG from Invitrogen, Carlsbad,
CA). After mounting, slides were examined by fluorescence microscopy.
Real-time PCR
Total RNA was isolated from kidney glomeruli of mice using TRIzol
(Invitrogen). Real-time PCR was performed with a Roche Light-
cycler (Roche Applied Science, Indianapolis, IN) and Qiagen
QuantiTect SYBR green PCR kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. Predesigned primer sets were
obtained from Qiagen (GeneGlobe) for synaptopodin, nephrin,
WT-1, cyclin E, Ki67, RARa, RARb, RORE, Cyp26A, RDH1, and
RDH9. The following sequences were used for the tubulin primers:
50-TGCCTTTGTGCACTGGTATG-30 and 50-CTGGAGCAGTTTG
ACGACAC-30. Light cycler analysis software was used to determine
crossing points using the second derivative method. Data were
normalized to housekeeping genes (tubulin) and presented as
fold increase compared with RNA isolated from WT animals using
the 2DDCT method.
Western blot analysis
Glomerular lysates were subjected to western blot analysis using the
following specific antibodies including: rabbit anti-synaptopodin (a gift
from Dr Peter Mundel, University of Miami), rabbit anti-nephrin
(a gift from Dr Tomoko Takano, McGill University Health Centre),
anti-Ki67 (Abcam, Cambridge, MA), anti-nestin (Santa Cruz Biotech-
nology), anti-cyclin E (EMD Chemicals, Gibbstown, NJ), anti-WT-1
(Santa Cruz Biotechnology), and anti-b-actin antibodies (Sigma-
Aldrich, St Louis, MO).
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Measurement of tissue retinoids by mass spectrometry as
described
Retinol and ATRA levels were determined as described.41,42 Briefly,
kidney tissue was homogenized in 0.9% NaCl. KOH/ethanol
(0.025N) was added to the homogenates, followed by extraction
with 10ml of hexane. The top (hexane) layer containing retinol was
removed and evaporated under nitrogen and then resolved by
reversed-phase high performance liquid chromatography and quan-
tified by their ultraviolet absorbance at 325 nm. The bottom layer was
then extracted with 4N HCl and followed by 10ml of hexane. The
resulting top layer containing ATRAwas evaporated and resolved by a
liquid chromatography/tandem mass spectrometry.
Glomerular enzymatic activity for RA acid synthesis
Glomeruli were isolated from Tg26 and little-matched WT mice
(n¼ 5) by the graded sieving method. The purity of isolated
glomeruli was verified under microscope.
Glomeruli were homogenized by motor-driven homogenizer in
the presence of a buffer containing 10% sucrose (w/w), 10mmol/l
Tris-HCl, 1mmol/l EDTA, 1.5mmol/l dithiothreitol, pH¼ 7.4, and
protease inhibitors. Protein concentration was determined by the
bicinchoninic acid method.
The enzymatic activity for RA acid synthesis was determined by
measuring the conversion of retinol (10 mM) to RA in the presence
of glomerular lysates (30 mg) from either WT or Tg26 mice.
The reaction occurred in a buffer containing 50mmol/l HEPES,
pH¼ 8.0, 150mmol/l KCl, 1mmol/l EDTA, 2mmol/l dithiothreitol,
NADþ 4mmol/l, and NADPþ 2mmol/l at 37 1C for 30min and
was stop by placing assay tubes into liquid nitrogen, and RA acid
levels were measured as described above. The enzymatic activity for
RA synthesis was expressed as pmol of RA generation per mg of
glomerular lysates per min of incubation (pmol/mg/min).
Statistical analysis
Data were expressed as mean±s.d.. The unpaired t-test was used to
analyze data between two groups. Statistical significance will be
considered when Po0.05.
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